When claiming for Zostavax and influenza vaccines given on the same day, via Medtech PMS, both vaccines are being automatically auto-billed (ticked) when only one claim should be made.
Medtech recommends practices untick the auto-bill function for one of the vaccines given. The advice is to enter the flu vaccine event first and have the auto-bill ticked for this entry, as this will ensure you receive reimbursement for the vaccine cost as well as the immunisation subsidy. Then enter the Zostavax event and untick the auto-bill box.
This method of unticking the auto-bill will require practices reinstate the auto-bill prior, or at the next claimable/billable event, when applicable (such as when only one vaccine has been given).
Medtech is working to find a solution so these vaccines can be grouped to generate only one claim, as well as keeping the existing option of individually generating a claim for each vaccine when given on different days.
A solution may be some time away and we recommend practices follow the suggested workaround until further notice.
MyPractice PMS defaults to billing for only one vaccine when both are given at the same time. For other PMS systems, please check the function that occurs to create a claim and make sure you are only generating one claim onto your schedules. If this is occurring similarly to Medtech, enter and claim the flu vaccine event first.
The Ministry of Health is yet to advise on the over payment so this will be released as soon as it is known.
The IMAC 0800 line has received a significant volume of calls relating to the introduction of the Zostavax vaccine (shingles, HZV) and the flu season. Please download the IMAC updated chapters for the immunisation handbook on zoster, influenza, and vaccines for special groups as these are essential for decision making. Table 22.2 in the Zoster chapter is very useful when reviewing patients on immunosuppressive therapy.
The addition of the Zostavax vaccine to the adult schedule has prompted discussion about how best to manage this process well and safely.
It is IMAC's view that it is clinically appropriate, and the best use of patient time, to offer Zostavax to eligible patients when they are attending for another service, such as the flu vaccine.
We understand and support this view, but know each practice will have different resources and pressures, and we all want to keep patient safety at the top of the list.
Extra resources for additional costs of administration would be nice, and whilst we will raise this at the PSAAP negotiations, this is only one issue of many that will be discussed, and the counter-argument is that only one administration fee is paid for other joint vaccination events such as those in childhood.
There are a number of points practices may consider.
If you need to chat, or you have some ideas you would like to share, let us know.